nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2D6—breast cancer	0.124	0.389	CbGaD
Levomilnacipran—CYP3A4—breast cancer	0.107	0.334	CbGaD
Levomilnacipran—ABCB1—breast cancer	0.0888	0.278	CbGaD
Levomilnacipran—CYP2C8—Lapatinib—breast cancer	0.0262	0.0616	CbGbCtD
Levomilnacipran—ABCB1—Toremifene—breast cancer	0.0243	0.0572	CbGbCtD
Levomilnacipran—CYP2C19—Lapatinib—breast cancer	0.0219	0.0517	CbGbCtD
Levomilnacipran—CYP3A4—Exemestane—breast cancer	0.021	0.0494	CbGbCtD
Levomilnacipran—CYP2C8—Raloxifene—breast cancer	0.0198	0.0467	CbGbCtD
Levomilnacipran—CYP2D6—Idarubicin—breast cancer	0.0189	0.0446	CbGbCtD
Levomilnacipran—CYP3A4—Letrozole—breast cancer	0.0178	0.042	CbGbCtD
Levomilnacipran—ABCB1—Lapatinib—breast cancer	0.0177	0.0417	CbGbCtD
Levomilnacipran—CYP3A4—Anastrozole—breast cancer	0.0159	0.0375	CbGbCtD
Levomilnacipran—CYP3A4—Toremifene—breast cancer	0.0145	0.0343	CbGbCtD
Levomilnacipran—CYP3A4—Fulvestrant—breast cancer	0.0135	0.0319	CbGbCtD
Levomilnacipran—CYP2C8—Tamoxifen—breast cancer	0.0131	0.0309	CbGbCtD
Levomilnacipran—CYP3A4—Thiotepa—breast cancer	0.012	0.0284	CbGbCtD
Levomilnacipran—CYP3A4—Ixabepilone—breast cancer	0.011	0.026	CbGbCtD
Levomilnacipran—CYP2C19—Tamoxifen—breast cancer	0.011	0.0259	CbGbCtD
Levomilnacipran—CYP3A4—Lapatinib—breast cancer	0.0106	0.025	CbGbCtD
Levomilnacipran—CYP2C8—Paclitaxel—breast cancer	0.0102	0.024	CbGbCtD
Levomilnacipran—ABCB1—Vinorelbine—breast cancer	0.00982	0.0231	CbGbCtD
Levomilnacipran—CYP2C8—Fluorouracil—breast cancer	0.00965	0.0227	CbGbCtD
Levomilnacipran—CYP2D6—Vinorelbine—breast cancer	0.00925	0.0218	CbGbCtD
Levomilnacipran—ABCB1—Tamoxifen—breast cancer	0.00886	0.0209	CbGbCtD
Levomilnacipran—ABCB1—Mitoxantrone—breast cancer	0.00865	0.0204	CbGbCtD
Levomilnacipran—CYP2D6—Tamoxifen—breast cancer	0.00835	0.0197	CbGbCtD
Levomilnacipran—CYP3A4—Raloxifene—breast cancer	0.00804	0.0189	CbGbCtD
Levomilnacipran—ABCB1—Gemcitabine—breast cancer	0.00764	0.018	CbGbCtD
Levomilnacipran—ABCB1—Paclitaxel—breast cancer	0.0069	0.0163	CbGbCtD
Levomilnacipran—ABCB1—Irinotecan—breast cancer	0.00681	0.016	CbGbCtD
Levomilnacipran—ABCB1—Vinblastine—breast cancer	0.00605	0.0143	CbGbCtD
Levomilnacipran—CYP3A4—Vinorelbine—breast cancer	0.00588	0.0139	CbGbCtD
Levomilnacipran—CYP2D6—Vinblastine—breast cancer	0.0057	0.0134	CbGbCtD
Levomilnacipran—CYP3A4—Tamoxifen—breast cancer	0.00531	0.0125	CbGbCtD
Levomilnacipran—CYP3A4—Mitoxantrone—breast cancer	0.00518	0.0122	CbGbCtD
Levomilnacipran—ABCB1—Docetaxel—breast cancer	0.00499	0.0118	CbGbCtD
Levomilnacipran—CYP3A4—Paclitaxel—breast cancer	0.00413	0.00974	CbGbCtD
Levomilnacipran—CYP3A4—Irinotecan—breast cancer	0.00408	0.00961	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—breast cancer	0.00372	0.00876	CbGbCtD
Levomilnacipran—CYP3A4—Vinblastine—breast cancer	0.00363	0.00854	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—breast cancer	0.0036	0.00849	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—breast cancer	0.0035	0.00826	CbGbCtD
Levomilnacipran—CYP3A4—Docetaxel—breast cancer	0.00299	0.00704	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—breast cancer	0.00223	0.00525	CbGbCtD
Levomilnacipran—CYP2J2—nipple—breast cancer	0.000852	0.113	CbGeAlD
Levomilnacipran—CYP2J2—skin of body—breast cancer	0.000546	0.0724	CbGeAlD
Levomilnacipran—CYP2J2—endometrium—breast cancer	0.000515	0.0683	CbGeAlD
Levomilnacipran—CYP2J2—uterus—breast cancer	0.000474	0.0629	CbGeAlD
Levomilnacipran—CYP2J2—pituitary gland—breast cancer	0.000466	0.0618	CbGeAlD
Levomilnacipran—CYP2J2—female reproductive system—breast cancer	0.000426	0.0566	CbGeAlD
Levomilnacipran—CYP2C8—mammary gland—breast cancer	0.000402	0.0533	CbGeAlD
Levomilnacipran—CYP2J2—endocrine gland—breast cancer	0.000361	0.0479	CbGeAlD
Levomilnacipran—SLC6A4—female reproductive system—breast cancer	0.00023	0.0305	CbGeAlD
Levomilnacipran—SLC6A2—female reproductive system—breast cancer	0.000202	0.0269	CbGeAlD
Levomilnacipran—CYP2C8—endometrium—breast cancer	0.000201	0.0266	CbGeAlD
Levomilnacipran—SLC6A2—adrenal gland—breast cancer	0.000197	0.0262	CbGeAlD
Levomilnacipran—SLC6A4—endocrine gland—breast cancer	0.000195	0.0258	CbGeAlD
Levomilnacipran—CYP2C8—pituitary gland—breast cancer	0.000182	0.0241	CbGeAlD
Levomilnacipran—SLC6A2—endocrine gland—breast cancer	0.000171	0.0227	CbGeAlD
Levomilnacipran—CYP2C8—female reproductive system—breast cancer	0.000166	0.0221	CbGeAlD
Levomilnacipran—CYP2C19—endocrine gland—breast cancer	0.000161	0.0214	CbGeAlD
Levomilnacipran—CYP2C8—endocrine gland—breast cancer	0.000141	0.0187	CbGeAlD
Levomilnacipran—ABCB1—embryo—breast cancer	0.000131	0.0175	CbGeAlD
Levomilnacipran—SLC6A2—lymph node—breast cancer	0.000118	0.0157	CbGeAlD
Levomilnacipran—CYP3A4—female reproductive system—breast cancer	0.000113	0.0149	CbGeAlD
Levomilnacipran—CYP2D6—female reproductive system—breast cancer	0.000111	0.0147	CbGeAlD
Levomilnacipran—ABCB1—epithelium—breast cancer	0.000107	0.0142	CbGeAlD
Levomilnacipran—CYP2D6—female gonad—breast cancer	0.000101	0.0134	CbGeAlD
Levomilnacipran—ABCB1—endometrium—breast cancer	9.62e-05	0.0128	CbGeAlD
Levomilnacipran—CYP3A4—endocrine gland—breast cancer	9.53e-05	0.0126	CbGeAlD
Levomilnacipran—CYP2D6—endocrine gland—breast cancer	9.38e-05	0.0124	CbGeAlD
Levomilnacipran—ABCB1—uterus—breast cancer	8.87e-05	0.0118	CbGeAlD
Levomilnacipran—ABCB1—pituitary gland—breast cancer	8.71e-05	0.0116	CbGeAlD
Levomilnacipran—ABCB1—adipose tissue—breast cancer	8.67e-05	0.0115	CbGeAlD
Levomilnacipran—ABCB1—female reproductive system—breast cancer	7.97e-05	0.0106	CbGeAlD
Levomilnacipran—ABCB1—adrenal gland—breast cancer	7.78e-05	0.0103	CbGeAlD
Levomilnacipran—ABCB1—bone marrow—breast cancer	7.52e-05	0.00999	CbGeAlD
Levomilnacipran—ABCB1—female gonad—breast cancer	7.25e-05	0.00963	CbGeAlD
Levomilnacipran—ABCB1—endocrine gland—breast cancer	6.74e-05	0.00895	CbGeAlD
Levomilnacipran—Tachycardia—Capecitabine—breast cancer	4.88e-05	0.000293	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—breast cancer	4.88e-05	0.000293	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—breast cancer	4.87e-05	0.000292	CcSEcCtD
Levomilnacipran—Skin disorder—Capecitabine—breast cancer	4.86e-05	0.000292	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—breast cancer	4.85e-05	0.000291	CcSEcCtD
Levomilnacipran—Urticaria—Paclitaxel—breast cancer	4.85e-05	0.000291	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Capecitabine—breast cancer	4.84e-05	0.00029	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—breast cancer	4.83e-05	0.00029	CcSEcCtD
Levomilnacipran—Hypotension—Docetaxel—breast cancer	4.83e-05	0.00029	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—breast cancer	4.82e-05	0.00029	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—breast cancer	4.82e-05	0.00029	CcSEcCtD
Levomilnacipran—Abdominal pain—Paclitaxel—breast cancer	4.82e-05	0.000289	CcSEcCtD
Levomilnacipran—Body temperature increased—Paclitaxel—breast cancer	4.82e-05	0.000289	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—breast cancer	4.81e-05	0.000289	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—breast cancer	4.78e-05	0.000287	CcSEcCtD
Levomilnacipran—Anorexia—Capecitabine—breast cancer	4.77e-05	0.000286	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—breast cancer	4.76e-05	0.000286	CcSEcCtD
Levomilnacipran—Vomiting—Irinotecan—breast cancer	4.75e-05	0.000285	CcSEcCtD
Levomilnacipran—Vomiting—Mitoxantrone—breast cancer	4.75e-05	0.000285	CcSEcCtD
Levomilnacipran—Dizziness—Fluorouracil—breast cancer	4.74e-05	0.000284	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—breast cancer	4.73e-05	0.000284	CcSEcCtD
Levomilnacipran—Rash—Irinotecan—breast cancer	4.72e-05	0.000283	CcSEcCtD
Levomilnacipran—Rash—Mitoxantrone—breast cancer	4.72e-05	0.000283	CcSEcCtD
Levomilnacipran—Dermatitis—Mitoxantrone—breast cancer	4.71e-05	0.000283	CcSEcCtD
Levomilnacipran—Dermatitis—Irinotecan—breast cancer	4.71e-05	0.000283	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—breast cancer	4.71e-05	0.000282	CcSEcCtD
Levomilnacipran—Headache—Mitoxantrone—breast cancer	4.68e-05	0.000281	CcSEcCtD
Levomilnacipran—Headache—Irinotecan—breast cancer	4.68e-05	0.000281	CcSEcCtD
Levomilnacipran—Hypotension—Capecitabine—breast cancer	4.68e-05	0.000281	CcSEcCtD
Levomilnacipran—Insomnia—Docetaxel—breast cancer	4.68e-05	0.000281	CcSEcCtD
Levomilnacipran—ABCB1—lymph node—breast cancer	4.66e-05	0.00619	CbGeAlD
Levomilnacipran—Paraesthesia—Docetaxel—breast cancer	4.64e-05	0.000279	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—breast cancer	4.64e-05	0.000279	CcSEcCtD
Levomilnacipran—Vomiting—Gemcitabine—breast cancer	4.63e-05	0.000278	CcSEcCtD
Levomilnacipran—Dyspnoea—Docetaxel—breast cancer	4.61e-05	0.000277	CcSEcCtD
Levomilnacipran—Somnolence—Docetaxel—breast cancer	4.6e-05	0.000276	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—breast cancer	4.59e-05	0.000276	CcSEcCtD
Levomilnacipran—Rash—Gemcitabine—breast cancer	4.59e-05	0.000276	CcSEcCtD
Levomilnacipran—Dermatitis—Gemcitabine—breast cancer	4.59e-05	0.000275	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—breast cancer	4.59e-05	0.000275	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—breast cancer	4.57e-05	0.000274	CcSEcCtD
Levomilnacipran—Headache—Gemcitabine—breast cancer	4.56e-05	0.000274	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—breast cancer	4.55e-05	0.000273	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—breast cancer	4.55e-05	0.000273	CcSEcCtD
Levomilnacipran—Vomiting—Fluorouracil—breast cancer	4.55e-05	0.000273	CcSEcCtD
Levomilnacipran—Dyspepsia—Docetaxel—breast cancer	4.55e-05	0.000273	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—breast cancer	4.54e-05	0.000273	CcSEcCtD
Levomilnacipran—Insomnia—Capecitabine—breast cancer	4.53e-05	0.000272	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—breast cancer	4.52e-05	0.000271	CcSEcCtD
Levomilnacipran—Rash—Fluorouracil—breast cancer	4.52e-05	0.000271	CcSEcCtD
Levomilnacipran—Dermatitis—Fluorouracil—breast cancer	4.51e-05	0.000271	CcSEcCtD
Levomilnacipran—Paraesthesia—Capecitabine—breast cancer	4.49e-05	0.00027	CcSEcCtD
Levomilnacipran—Decreased appetite—Docetaxel—breast cancer	4.49e-05	0.00027	CcSEcCtD
Levomilnacipran—Hypersensitivity—Paclitaxel—breast cancer	4.49e-05	0.00027	CcSEcCtD
Levomilnacipran—Headache—Fluorouracil—breast cancer	4.49e-05	0.000269	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—breast cancer	4.48e-05	0.000269	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—breast cancer	4.47e-05	0.000269	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—breast cancer	4.47e-05	0.000268	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Docetaxel—breast cancer	4.46e-05	0.000268	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—breast cancer	4.46e-05	0.000268	CcSEcCtD
Levomilnacipran—Dyspnoea—Capecitabine—breast cancer	4.46e-05	0.000268	CcSEcCtD
Levomilnacipran—Fatigue—Docetaxel—breast cancer	4.46e-05	0.000268	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—breast cancer	4.45e-05	0.000267	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—breast cancer	4.45e-05	0.000267	CcSEcCtD
Levomilnacipran—Nausea—Mitoxantrone—breast cancer	4.44e-05	0.000267	CcSEcCtD
Levomilnacipran—Nausea—Irinotecan—breast cancer	4.44e-05	0.000267	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—breast cancer	4.42e-05	0.000266	CcSEcCtD
Levomilnacipran—Constipation—Docetaxel—breast cancer	4.42e-05	0.000265	CcSEcCtD
Levomilnacipran—Dyspepsia—Capecitabine—breast cancer	4.41e-05	0.000264	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—breast cancer	4.4e-05	0.000264	CcSEcCtD
Levomilnacipran—Asthenia—Paclitaxel—breast cancer	4.38e-05	0.000263	CcSEcCtD
Levomilnacipran—Decreased appetite—Capecitabine—breast cancer	4.35e-05	0.000261	CcSEcCtD
Levomilnacipran—Nausea—Gemcitabine—breast cancer	4.33e-05	0.00026	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Capecitabine—breast cancer	4.32e-05	0.000259	CcSEcCtD
Levomilnacipran—Fatigue—Capecitabine—breast cancer	4.32e-05	0.000259	CcSEcCtD
Levomilnacipran—Pruritus—Paclitaxel—breast cancer	4.32e-05	0.000259	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—breast cancer	4.3e-05	0.000258	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—breast cancer	4.3e-05	0.000258	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—breast cancer	4.29e-05	0.000258	CcSEcCtD
Levomilnacipran—Constipation—Capecitabine—breast cancer	4.28e-05	0.000257	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—breast cancer	4.27e-05	0.000256	CcSEcCtD
Levomilnacipran—Nausea—Fluorouracil—breast cancer	4.25e-05	0.000255	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—breast cancer	4.24e-05	0.000255	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Docetaxel—breast cancer	4.23e-05	0.000254	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—breast cancer	4.21e-05	0.000253	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—breast cancer	4.21e-05	0.000253	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—breast cancer	4.21e-05	0.000253	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—breast cancer	4.19e-05	0.000252	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—breast cancer	4.18e-05	0.000251	CcSEcCtD
Levomilnacipran—Diarrhoea—Paclitaxel—breast cancer	4.17e-05	0.000251	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—breast cancer	4.12e-05	0.000247	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Capecitabine—breast cancer	4.09e-05	0.000246	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—breast cancer	4.09e-05	0.000246	CcSEcCtD
Levomilnacipran—Body temperature increased—Docetaxel—breast cancer	4.09e-05	0.000245	CcSEcCtD
Levomilnacipran—Abdominal pain—Docetaxel—breast cancer	4.09e-05	0.000245	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—breast cancer	4.09e-05	0.000245	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—breast cancer	4.07e-05	0.000245	CcSEcCtD
Levomilnacipran—Dizziness—Paclitaxel—breast cancer	4.03e-05	0.000242	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—breast cancer	4.03e-05	0.000242	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—breast cancer	3.98e-05	0.000239	CcSEcCtD
Levomilnacipran—Urticaria—Capecitabine—breast cancer	3.98e-05	0.000239	CcSEcCtD
Levomilnacipran—Abdominal pain—Capecitabine—breast cancer	3.96e-05	0.000238	CcSEcCtD
Levomilnacipran—Body temperature increased—Capecitabine—breast cancer	3.96e-05	0.000238	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—breast cancer	3.96e-05	0.000237	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—breast cancer	3.95e-05	0.000237	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—breast cancer	3.93e-05	0.000236	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—breast cancer	3.9e-05	0.000234	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—breast cancer	3.89e-05	0.000233	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—breast cancer	3.88e-05	0.000233	CcSEcCtD
Levomilnacipran—Vomiting—Paclitaxel—breast cancer	3.88e-05	0.000233	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—breast cancer	3.87e-05	0.000232	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.86e-05	0.000232	CcSEcCtD
Levomilnacipran—Rash—Paclitaxel—breast cancer	3.85e-05	0.000231	CcSEcCtD
Levomilnacipran—Dermatitis—Paclitaxel—breast cancer	3.84e-05	0.000231	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—breast cancer	3.83e-05	0.00023	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—breast cancer	3.82e-05	0.00023	CcSEcCtD
Levomilnacipran—Headache—Paclitaxel—breast cancer	3.82e-05	0.000229	CcSEcCtD
Levomilnacipran—Hypersensitivity—Docetaxel—breast cancer	3.81e-05	0.000229	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—breast cancer	3.78e-05	0.000227	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—breast cancer	3.76e-05	0.000225	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—breast cancer	3.73e-05	0.000224	CcSEcCtD
Levomilnacipran—Asthenia—Docetaxel—breast cancer	3.71e-05	0.000223	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—breast cancer	3.7e-05	0.000222	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—breast cancer	3.7e-05	0.000222	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—breast cancer	3.69e-05	0.000221	CcSEcCtD
Levomilnacipran—Hypersensitivity—Capecitabine—breast cancer	3.69e-05	0.000221	CcSEcCtD
Levomilnacipran—Pruritus—Docetaxel—breast cancer	3.66e-05	0.00022	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—breast cancer	3.65e-05	0.000219	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—breast cancer	3.65e-05	0.000219	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—breast cancer	3.64e-05	0.000218	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—breast cancer	3.63e-05	0.000218	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—breast cancer	3.62e-05	0.000218	CcSEcCtD
Levomilnacipran—Nausea—Paclitaxel—breast cancer	3.62e-05	0.000217	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—breast cancer	3.62e-05	0.000217	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.61e-05	0.000217	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—breast cancer	3.6e-05	0.000216	CcSEcCtD
Levomilnacipran—Asthenia—Capecitabine—breast cancer	3.59e-05	0.000216	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—breast cancer	3.56e-05	0.000214	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—breast cancer	3.55e-05	0.000213	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—breast cancer	3.55e-05	0.000213	CcSEcCtD
Levomilnacipran—Pruritus—Capecitabine—breast cancer	3.54e-05	0.000213	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—breast cancer	3.54e-05	0.000212	CcSEcCtD
Levomilnacipran—Diarrhoea—Docetaxel—breast cancer	3.54e-05	0.000212	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—breast cancer	3.49e-05	0.00021	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—breast cancer	3.48e-05	0.000209	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—breast cancer	3.47e-05	0.000209	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—breast cancer	3.46e-05	0.000208	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—breast cancer	3.43e-05	0.000206	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—breast cancer	3.43e-05	0.000206	CcSEcCtD
Levomilnacipran—Diarrhoea—Capecitabine—breast cancer	3.42e-05	0.000206	CcSEcCtD
Levomilnacipran—Pethidine—CYP2D6—breast cancer	3.42e-05	0.384	CrCbGaD
Levomilnacipran—Nervous system disorder—Epirubicin—breast cancer	3.42e-05	0.000205	CcSEcCtD
Levomilnacipran—Dizziness—Docetaxel—breast cancer	3.42e-05	0.000205	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—breast cancer	3.41e-05	0.000205	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—breast cancer	3.41e-05	0.000205	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—breast cancer	3.4e-05	0.000204	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—breast cancer	3.39e-05	0.000203	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—breast cancer	3.37e-05	0.000202	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—breast cancer	3.37e-05	0.000202	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—breast cancer	3.37e-05	0.000202	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—breast cancer	3.35e-05	0.000201	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—breast cancer	3.35e-05	0.000201	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.34e-05	0.000201	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—breast cancer	3.32e-05	0.0002	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—breast cancer	3.32e-05	0.000199	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—breast cancer	3.31e-05	0.000199	CcSEcCtD
Levomilnacipran—Dizziness—Capecitabine—breast cancer	3.31e-05	0.000199	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—breast cancer	3.29e-05	0.000198	CcSEcCtD
Levomilnacipran—Vomiting—Docetaxel—breast cancer	3.29e-05	0.000197	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—breast cancer	3.28e-05	0.000197	CcSEcCtD
Levomilnacipran—Rash—Docetaxel—breast cancer	3.26e-05	0.000196	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—breast cancer	3.26e-05	0.000196	CcSEcCtD
Levomilnacipran—Dermatitis—Docetaxel—breast cancer	3.26e-05	0.000195	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—breast cancer	3.24e-05	0.000194	CcSEcCtD
Levomilnacipran—Headache—Docetaxel—breast cancer	3.24e-05	0.000194	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—breast cancer	3.22e-05	0.000193	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—breast cancer	3.21e-05	0.000193	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—breast cancer	3.21e-05	0.000192	CcSEcCtD
Levomilnacipran—Vomiting—Capecitabine—breast cancer	3.18e-05	0.000191	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—breast cancer	3.17e-05	0.000191	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—breast cancer	3.16e-05	0.00019	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—breast cancer	3.16e-05	0.00019	CcSEcCtD
Levomilnacipran—Rash—Capecitabine—breast cancer	3.16e-05	0.000189	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—breast cancer	3.15e-05	0.000189	CcSEcCtD
Levomilnacipran—Dermatitis—Capecitabine—breast cancer	3.15e-05	0.000189	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—breast cancer	3.15e-05	0.000189	CcSEcCtD
Levomilnacipran—Headache—Capecitabine—breast cancer	3.14e-05	0.000188	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—breast cancer	3.13e-05	0.000188	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—breast cancer	3.13e-05	0.000188	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—breast cancer	3.12e-05	0.000187	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—breast cancer	3.11e-05	0.000187	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—breast cancer	3.1e-05	0.000186	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—breast cancer	3.08e-05	0.000185	CcSEcCtD
Levomilnacipran—Nausea—Docetaxel—breast cancer	3.07e-05	0.000184	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—breast cancer	3.07e-05	0.000184	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—breast cancer	3.05e-05	0.000183	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—breast cancer	3.03e-05	0.000182	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—breast cancer	3.01e-05	0.000181	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—breast cancer	3.01e-05	0.000181	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—breast cancer	3.01e-05	0.00018	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—breast cancer	2.98e-05	0.000179	CcSEcCtD
Levomilnacipran—Nausea—Capecitabine—breast cancer	2.97e-05	0.000178	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—breast cancer	2.96e-05	0.000178	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—breast cancer	2.95e-05	0.000177	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—breast cancer	2.95e-05	0.000177	CcSEcCtD
Levomilnacipran—Pethidine—CYP3A4—breast cancer	2.94e-05	0.329	CrCbGaD
Levomilnacipran—Insomnia—Doxorubicin—breast cancer	2.92e-05	0.000175	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—breast cancer	2.9e-05	0.000174	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—breast cancer	2.88e-05	0.000173	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—breast cancer	2.87e-05	0.000172	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—breast cancer	2.85e-05	0.000171	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—breast cancer	2.84e-05	0.00017	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—breast cancer	2.8e-05	0.000168	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—breast cancer	2.79e-05	0.000167	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—breast cancer	2.78e-05	0.000167	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—breast cancer	2.77e-05	0.000166	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—breast cancer	2.76e-05	0.000166	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—breast cancer	2.76e-05	0.000165	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—breast cancer	2.76e-05	0.000165	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—breast cancer	2.75e-05	0.000165	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—breast cancer	2.67e-05	0.00016	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—breast cancer	2.64e-05	0.000158	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—breast cancer	2.64e-05	0.000158	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—breast cancer	2.57e-05	0.000154	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—breast cancer	2.56e-05	0.000154	CcSEcCtD
Levomilnacipran—Pethidine—ALB—breast cancer	2.56e-05	0.287	CrCbGaD
Levomilnacipran—Abdominal pain—Doxorubicin—breast cancer	2.55e-05	0.000153	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—breast cancer	2.55e-05	0.000153	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—breast cancer	2.55e-05	0.000153	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—breast cancer	2.5e-05	0.00015	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—breast cancer	2.47e-05	0.000148	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—breast cancer	2.46e-05	0.000148	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—breast cancer	2.39e-05	0.000143	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—breast cancer	2.38e-05	0.000143	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—breast cancer	2.37e-05	0.000142	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—breast cancer	2.35e-05	0.000141	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—breast cancer	2.35e-05	0.000141	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—breast cancer	2.33e-05	0.00014	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—breast cancer	2.31e-05	0.000139	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—breast cancer	2.31e-05	0.000138	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—breast cancer	2.28e-05	0.000137	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—breast cancer	2.22e-05	0.000133	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—breast cancer	2.21e-05	0.000133	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—breast cancer	2.21e-05	0.000133	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—breast cancer	2.2e-05	0.000132	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—breast cancer	2.2e-05	0.000132	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—breast cancer	2.18e-05	0.000131	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—breast cancer	2.13e-05	0.000128	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—breast cancer	2.07e-05	0.000124	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—breast cancer	2.05e-05	0.000123	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—breast cancer	2.03e-05	0.000122	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—breast cancer	2.03e-05	0.000122	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—breast cancer	2.02e-05	0.000121	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—breast cancer	1.92e-05	0.000115	CcSEcCtD
Levomilnacipran—ABCB1—Metabolism—HPGDS—breast cancer	5.45e-06	6.69e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HBA1—breast cancer	5.42e-06	6.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ACHE—breast cancer	5.42e-06	6.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—breast cancer	5.42e-06	6.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA3—breast cancer	5.39e-06	6.61e-05	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—breast cancer	5.37e-06	6.59e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC2A2—breast cancer	5.35e-06	6.56e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UMPS—breast cancer	5.32e-06	6.52e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADSL—breast cancer	5.32e-06	6.52e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PHGDH—breast cancer	5.32e-06	6.52e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FHL2—breast cancer	5.32e-06	6.52e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NME1—breast cancer	5.32e-06	6.52e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—FASN—breast cancer	5.31e-06	6.52e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—breast cancer	5.29e-06	6.49e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ACHE—breast cancer	5.29e-06	6.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BCHE—breast cancer	5.29e-06	6.49e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCG2—breast cancer	5.24e-06	6.43e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CPT1A—breast cancer	5.24e-06	6.43e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTR—breast cancer	5.24e-06	6.43e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC5A5—breast cancer	5.22e-06	6.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HPSE—breast cancer	5.21e-06	6.4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BRIP1—breast cancer	5.21e-06	6.4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LDHB—breast cancer	5.21e-06	6.4e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HPGDS—breast cancer	5.14e-06	6.31e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	5.13e-06	6.3e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP17A1—breast cancer	5.13e-06	6.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HBA1—breast cancer	5.11e-06	6.27e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ENO1—breast cancer	5.08e-06	6.23e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS1—breast cancer	5.08e-06	6.23e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	5.06e-06	6.21e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NQO1—breast cancer	5.05e-06	6.19e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC2A1—breast cancer	5.05e-06	6.19e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP17A1—breast cancer	5.01e-06	6.14e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—breast cancer	4.99e-06	6.13e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—breast cancer	4.98e-06	6.12e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ACHE—breast cancer	4.98e-06	6.12e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2D6—breast cancer	4.98e-06	6.11e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ENO1—breast cancer	4.96e-06	6.08e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS1—breast cancer	4.96e-06	6.08e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCC1—breast cancer	4.94e-06	6.07e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA3—breast cancer	4.94e-06	6.07e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMMR—breast cancer	4.94e-06	6.07e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.94e-06	6.06e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP3A4—breast cancer	4.92e-06	6.04e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.9e-06	6.01e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOA2—breast cancer	4.89e-06	6e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2D6—breast cancer	4.86e-06	5.96e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1B1—breast cancer	4.84e-06	5.94e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARGC1B—breast cancer	4.79e-06	5.87e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOA2—breast cancer	4.77e-06	5.85e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HSP90AA1—breast cancer	4.74e-06	5.82e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FASN—breast cancer	4.74e-06	5.82e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BCHE—breast cancer	4.72e-06	5.79e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP17A1—breast cancer	4.72e-06	5.79e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS1—breast cancer	4.67e-06	5.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ENO1—breast cancer	4.67e-06	5.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC5A5—breast cancer	4.66e-06	5.72e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	4.64e-06	5.69e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FASN—breast cancer	4.63e-06	5.68e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOA1—breast cancer	4.61e-06	5.66e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BCHE—breast cancer	4.61e-06	5.65e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC5A5—breast cancer	4.55e-06	5.59e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP19A1—breast cancer	4.55e-06	5.58e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—STK11—breast cancer	4.55e-06	5.58e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA9—breast cancer	4.52e-06	5.55e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA4—breast cancer	4.52e-06	5.55e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NQO1—breast cancer	4.5e-06	5.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC2A1—breast cancer	4.5e-06	5.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA2—breast cancer	4.5e-06	5.52e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.41e-06	5.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA2—breast cancer	4.41e-06	5.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX2—breast cancer	4.41e-06	5.41e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NQO1—breast cancer	4.4e-06	5.39e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC2A1—breast cancer	4.4e-06	5.39e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP3A4—breast cancer	4.39e-06	5.39e-05	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—breast cancer	4.39e-06	5.39e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.37e-06	5.36e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FASN—breast cancer	4.36e-06	5.35e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX4—breast cancer	4.35e-06	5.34e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SULT1A1—breast cancer	4.35e-06	5.34e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BCHE—breast cancer	4.34e-06	5.33e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1B1—breast cancer	4.32e-06	5.3e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC5A5—breast cancer	4.29e-06	5.26e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP3A4—breast cancer	4.29e-06	5.26e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.27e-06	5.24e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTA1—breast cancer	4.25e-06	5.22e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—IDH1—breast cancer	4.25e-06	5.22e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HSP90AA1—breast cancer	4.23e-06	5.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—COMT—breast cancer	4.23e-06	5.19e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1B1—breast cancer	4.21e-06	5.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—breast cancer	4.21e-06	5.16e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAT2—breast cancer	4.2e-06	5.16e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	4.19e-06	5.14e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMOX1—breast cancer	4.15e-06	5.09e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC2A1—breast cancer	4.14e-06	5.08e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NQO1—breast cancer	4.14e-06	5.08e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ITPR1—breast cancer	4.14e-06	5.08e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HSP90AA1—breast cancer	4.13e-06	5.07e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOA1—breast cancer	4.12e-06	5.05e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP19A1—breast cancer	4.06e-06	4.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—STK11—breast cancer	4.06e-06	4.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP3A4—breast cancer	4.04e-06	4.96e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOA1—breast cancer	4.02e-06	4.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCB1—breast cancer	3.98e-06	4.89e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1B1—breast cancer	3.97e-06	4.87e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—STK11—breast cancer	3.96e-06	4.86e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP19A1—breast cancer	3.96e-06	4.86e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMS—breast cancer	3.91e-06	4.8e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HSP90AA1—breast cancer	3.89e-06	4.78e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLA2G4A—breast cancer	3.87e-06	4.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOR1—breast cancer	3.87e-06	4.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—breast cancer	3.87e-06	4.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.81e-06	4.68e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA1—breast cancer	3.79e-06	4.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—COMT—breast cancer	3.77e-06	4.63e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—breast cancer	3.76e-06	4.61e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—STK11—breast cancer	3.73e-06	4.58e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP19A1—breast cancer	3.73e-06	4.58e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMOX1—breast cancer	3.7e-06	4.55e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPX1—breast cancer	3.7e-06	4.54e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ITPR1—breast cancer	3.7e-06	4.54e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MED12—breast cancer	3.69e-06	4.52e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DPYD—breast cancer	3.69e-06	4.52e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—COMT—breast cancer	3.68e-06	4.52e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—breast cancer	3.67e-06	4.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1A1—breast cancer	3.67e-06	4.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ERCC2—breast cancer	3.64e-06	4.46e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALDOA—breast cancer	3.63e-06	4.45e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMOX1—breast cancer	3.62e-06	4.44e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ITPR1—breast cancer	3.61e-06	4.43e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCB1—breast cancer	3.56e-06	4.36e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA3—breast cancer	3.52e-06	4.32e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC2A2—breast cancer	3.5e-06	4.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMS—breast cancer	3.49e-06	4.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—COMT—breast cancer	3.47e-06	4.26e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—breast cancer	3.45e-06	4.24e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLA2G4A—breast cancer	3.45e-06	4.24e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—breast cancer	3.45e-06	4.24e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOR1—breast cancer	3.45e-06	4.24e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCG2—breast cancer	3.43e-06	4.2e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTR—breast cancer	3.43e-06	4.2e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CPT1A—breast cancer	3.43e-06	4.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—breast cancer	3.42e-06	4.19e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMS—breast cancer	3.41e-06	4.18e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMOX1—breast cancer	3.41e-06	4.18e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ITPR1—breast cancer	3.4e-06	4.17e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOR1—breast cancer	3.37e-06	4.13e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—breast cancer	3.37e-06	4.13e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLA2G4A—breast cancer	3.37e-06	4.13e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HPGDS—breast cancer	3.36e-06	4.12e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HBA1—breast cancer	3.34e-06	4.1e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPX1—breast cancer	3.31e-06	4.06e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1A1—breast cancer	3.27e-06	4.02e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCB1—breast cancer	3.27e-06	4.01e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ACHE—breast cancer	3.26e-06	4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—breast cancer	3.26e-06	4e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ERCC2—breast cancer	3.25e-06	3.98e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPX1—breast cancer	3.23e-06	3.96e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMS—breast cancer	3.21e-06	3.94e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1A1—breast cancer	3.19e-06	3.92e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.17e-06	3.9e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOR1—breast cancer	3.17e-06	3.9e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—breast cancer	3.17e-06	3.9e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ERCC2—breast cancer	3.17e-06	3.89e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CAV1—breast cancer	3.15e-06	3.87e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP17A1—breast cancer	3.08e-06	3.79e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS1—breast cancer	3.05e-06	3.75e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ENO1—breast cancer	3.05e-06	3.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—breast cancer	3.05e-06	3.74e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPX1—breast cancer	3.04e-06	3.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.01e-06	3.7e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1A1—breast cancer	3.01e-06	3.69e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2D6—breast cancer	2.99e-06	3.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ERCC2—breast cancer	2.98e-06	3.66e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—breast cancer	2.98e-06	3.65e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA2—breast cancer	2.94e-06	3.61e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—breast cancer	2.87e-06	3.52e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FASN—breast cancer	2.85e-06	3.5e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BCHE—breast cancer	2.84e-06	3.48e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CAV1—breast cancer	2.81e-06	3.45e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—breast cancer	2.81e-06	3.44e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC5A5—breast cancer	2.8e-06	3.44e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CAV1—breast cancer	2.75e-06	3.37e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NQO1—breast cancer	2.71e-06	3.32e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC2A1—breast cancer	2.71e-06	3.32e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.69e-06	3.3e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1B1—breast cancer	2.6e-06	3.19e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CAV1—breast cancer	2.59e-06	3.18e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—breast cancer	2.56e-06	3.15e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.55e-06	3.12e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CD—breast cancer	2.52e-06	3.1e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—breast cancer	2.5e-06	3.07e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—breast cancer	2.49e-06	3.06e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA1—breast cancer	2.48e-06	3.04e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—STK11—breast cancer	2.44e-06	3e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP19A1—breast cancer	2.44e-06	3e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NOS3—breast cancer	2.38e-06	2.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—breast cancer	2.36e-06	2.89e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—COMT—breast cancer	2.27e-06	2.79e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—breast cancer	2.26e-06	2.77e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CD—breast cancer	2.25e-06	2.77e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMOX1—breast cancer	2.23e-06	2.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—breast cancer	2.22e-06	2.73e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ITPR1—breast cancer	2.22e-06	2.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CB—breast cancer	2.2e-06	2.7e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CD—breast cancer	2.2e-06	2.7e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—breast cancer	2.18e-06	2.68e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—breast cancer	2.17e-06	2.66e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCB1—breast cancer	2.14e-06	2.62e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NOS3—breast cancer	2.13e-06	2.61e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMS—breast cancer	2.1e-06	2.58e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NOS3—breast cancer	2.08e-06	2.55e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOR1—breast cancer	2.08e-06	2.55e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.08e-06	2.55e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—breast cancer	2.08e-06	2.55e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CD—breast cancer	2.07e-06	2.54e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—breast cancer	2.05e-06	2.51e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX1—breast cancer	1.99e-06	2.44e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1A1—breast cancer	1.97e-06	2.41e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CB—breast cancer	1.96e-06	2.41e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NOS3—breast cancer	1.96e-06	2.4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ERCC2—breast cancer	1.95e-06	2.39e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—breast cancer	1.95e-06	2.39e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CB—breast cancer	1.92e-06	2.35e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—breast cancer	1.9e-06	2.33e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—breast cancer	1.9e-06	2.33e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—breast cancer	1.83e-06	2.25e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CB—breast cancer	1.81e-06	2.22e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—breast cancer	1.79e-06	2.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—breast cancer	1.7e-06	2.08e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CAV1—breast cancer	1.69e-06	2.08e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—breast cancer	1.66e-06	2.03e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—breast cancer	1.56e-06	1.92e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—breast cancer	1.54e-06	1.89e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CD—breast cancer	1.35e-06	1.66e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—breast cancer	1.34e-06	1.65e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—breast cancer	1.34e-06	1.64e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NOS3—breast cancer	1.28e-06	1.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—breast cancer	1.2e-06	1.47e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CB—breast cancer	1.18e-06	1.45e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—breast cancer	1.17e-06	1.44e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—breast cancer	1.17e-06	1.43e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—breast cancer	1.1e-06	1.35e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—breast cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—breast cancer	1.02e-06	1.25e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—breast cancer	9.78e-07	1.2e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—breast cancer	9.55e-07	1.17e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—breast cancer	9e-07	1.1e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—breast cancer	7.2e-07	8.83e-06	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—breast cancer	5.88e-07	7.22e-06	CbGpPWpGaD
